TrialCardiovascular diabetology2017

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Dirk Müller-Wieland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.